Anjali Pawar
Anjali Pawar
Read 1 minute

Global Plasma Protease C1-inhibitor Treatment Market Share, Growth, Trends & Forecast to 2027

Image for post
Plasma Protease C1 Inhibitor Treatment

Global Plasma Protease C1 Inhibitor Treatment Market operating key players Pharmaceutical Company Limited, Pharming Technologies B.V., CSL Behring LLC, Inc., KalVista Pharmaceuticals, Inc, onis Pharmaceuticals, Centogene AG, and BioCryst Pharmaceuticals. Because of the rising number of cases of acute hereditary angioedema (HAE) and prevention, the market of global plasma protease C1-inhibitor therapy is expected to rise rapidly in the future. The development of a few C1-inhibitor medication versions, which may be given intravenously or subcutaneously, is considered a big breakthrough for individuals with HAE.

C1-inhibitor, Kallikrein inhibitor, and selective Bradykinin B2 receptor antagonist are the three medication classes that make up the global Plasma Protease C1 Inhibitor Treatment Market (Firazyr). Because these medications are widely utilized for the treatment of acute HAE and prevention, the C1-inhibitor segment retained the largest market share in 2016. Over the projected period, the Selective Bradykinin B2 Receptor category is expected to increase at the fastest rate. This is mostly due to key players' increased R&D operations for the development of novel C1-inhibitor deficiency medications that may be delivered subcutaneously.

Read more @

1 view